Shire Buying ViroPharma To Create Leading Rare Disease Group
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire is snapping up ViroPharma at a hefty premium to secure possession of C1 esterase inhibitor Cinryze and position the group as a formidable force in treatments for rare diseases.
You may also be interested in...
ViroPharma Talks Cinryze Sales, EU Launches
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.